North America Antibody Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration (Intravenous, Subcutaneous, and Others), By Format, By Source, By End User, By Disease Areas, By Country and Growth Forecast, 2023 - 2030

The North America Antibody Therapeutics Market would witness market growth of 13.7% CAGR during the forecast period (2023-2030).

The safety profile of antibody therapeutics represents a compelling factor in their adoption. The targeted nature of antibodies minimizes off-target effects and reduces the risk of adverse events. This attribute is especially crucial in chronic conditions or diseases that require long-term treatment, where maintaining a favorable safety profile is paramount to ensuring patient compliance and overall well-being. Antibody therapeutics align seamlessly with this ethos, allowing for the customization of therapies based on patient-specific factors. The ability to engineer antibodies for specific targets or patient populations enhancses treatment precision and response rates, contributing to the growing adoption of personalized therapeutic strategies.

Continuous advancements in antibody engineering and discovery technologies contribute to the expanding adoption of these therapeutics. Innovations such as phage display, hybridoma technology, and computational approaches have streamlined the development process, enabling the rapid identification and optimization of antibody candidates. This acceleration in drug development timelines aligns with the growing demand for efficient and effective therapeutic solutions. Antibody therapeutics play a pivotal role in the field of oncology. Monoclonal antibodies (mAbs) are designed to specifically target and bind to cancer cells or proteins associated with cancer growth. These antibodies can be tailored to inhibit critical signaling pathways for cancer cell survival, mark cancer cells for immune system destruction, or deliver cytotoxic agents directly to cancer cells. Examples include Rituximab, Trastuzumab, and Pembrolizumab, which have demonstrated efficacy in treating various cancers.

Rare diseases are incredibly diverse, encompassing various conditions that vary in their symptoms, underlying causes, and clinical manifestations in the US. Advances in medical research and diagnostic capabilities have led to the identification of new rare diseases in the US. The expansion of rare diseases has led to increased clinical trial activity focused on developing and testing antibody therapeutics in the US. Ongoing biotechnology and antibody engineering advancements have expanded the capabilities of developing targeted therapeutics in the US. As per a report by the US Food & Drug Administration updated in 2022, in the US, more than 30 million people suffer from more than 7,000 rare diseases. Due to the above-mentioned factors, the antibody therapeutics market will grow significantly in this region.

The US market dominated the North America Antibody Therapeutics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $165,924.2 million by 2030. The Canada market is experiencing a CAGR of 16.3% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 15.2% during (2023 - 2030).

Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Others. Based on Format, the market is segmented into, Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody fragment & Others. Based on Source, the market is segmented into Human, Humanized, and Chimeric. Based on End User, the market is segmented into Hospitals, Long-term care facilities, and Others. Based on Disease Areas, the market is segmented into Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Antibody Therapeutics Market is Predict to reach $631.3 Billion by 2030, at a CAGR of 14.4%

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Route of Administration

• Intravenous
• Subcutaneous
• Others

By Format

• Monoclonal Antibody
• Polyclonal Antibody Therapy
• Bispecific Antibody
• Antibody fragment & Others

By Source

• Human
• Humanized
• Chimeric

By End User

• Hospitals
• Long-term care facilities
• Other

By Disease Areas

• Autoimmune & Inflammatory Diseases
• Neurology
• Osteology
• Hematology
• Oncology
• Infectious Diseases
• Immunology
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• F.Hoffmann-La Roche Ltd
• AbbVie, Inc.
• Johnson & Johnson (Johnson & Johnson Services, Inc.)
• Merck KGaA
• Bristol Myers Squibb Company
• AstraZeneca PLC
• Sanofi S.A.
• Novartis AG
• Biogen, Inc.
• Amgen, Inc.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Antibody Therapeutics Market, by Route of Administration
1.4.2 North America Antibody Therapeutics Market, by Format
1.4.3 North America Antibody Therapeutics Market, by Source
1.4.4 North America Antibody Therapeutics Market, by End User
1.4.5 North America Antibody Therapeutics Market, by Disease Areas
1.4.6 North America Antibody Therapeutics Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis

Chapter 4. Strategies Deployed in Antibody Therapeutics market.

Chapter 5. North America Antibody Therapeutics Market by Route of Administration
5.1 North America Intravenous Market by Country
5.2 North America Subcutaneous Market by Country
5.3 North America Others Market by Country

Chapter 6. North America Antibody Therapeutics Market by Format
6.1 North America Monoclonal Antibody Market by Country
6.2 North America Polyclonal Antibody Therapy Market by Country
6.3 North America Bispecific Antibody Market by Country
6.4 North America Antibody fragment & Others Market by Country

Chapter 7. North America Antibody Therapeutics Market by Source
7.1 North America Human Market by Country
7.2 North America Humanized Market by Country
7.3 North America Chimeric Market by Country
7.4 North America Others Market by Country

Chapter 8. North America Antibody Therapeutics Market by End User
8.1 North America Hospitals Market by Country
8.2 North America Long-term care facilities Market by Country
8.3 North America Others Market by Country

Chapter 9. North America Antibody Therapeutics Market by Disease Areas
9.1 North America Autoimmune & Inflammatory Diseases Market by Country
9.2 North America Neurology Market by Country
9.3 North America Osteology Market by Country
9.4 North America Hematology Market by Country
9.5 North America Oncology Market by Country
9.6 North America Infectious Diseases Market by Country
9.7 North America Immunology Market by Country
9.8 North America Others Market by Country

Chapter 10. North America Antibody Therapeutics Market by Country
10.1 US Antibody Therapeutics Market
10.1.1 US Antibody Therapeutics Market by Route of Administration
10.1.2 US Antibody Therapeutics Market by Format
10.1.3 US Antibody Therapeutics Market by Source
10.1.4 US Antibody Therapeutics Market by End User
10.1.5 US Antibody Therapeutics Market by Disease Areas
10.2 Canada Antibody Therapeutics Market
10.2.1 Canada Antibody Therapeutics Market by Route of Administration
10.2.2 Canada Antibody Therapeutics Market by Format
10.2.3 Canada Antibody Therapeutics Market by Source
10.2.4 Canada Antibody Therapeutics Market by End User
10.2.5 Canada Antibody Therapeutics Market by Disease Areas
10.3 Mexico Antibody Therapeutics Market
10.3.1 Mexico Antibody Therapeutics Market by Route of Administration
10.3.2 Mexico Antibody Therapeutics Market by Format
10.3.3 Mexico Antibody Therapeutics Market by Source
10.3.4 Mexico Antibody Therapeutics Market by End User
10.3.5 Mexico Antibody Therapeutics Market by Disease Areas
10.4 Rest of North America Antibody Therapeutics Market
10.4.1 Rest of North America Antibody Therapeutics Market by Route of Administration
10.4.2 Rest of North America Antibody Therapeutics Market by Format
10.4.3 Rest of North America Antibody Therapeutics Market by Source
10.4.4 Rest of North America Antibody Therapeutics Market by End User
10.4.5 Rest of North America Antibody Therapeutics Market by Disease Areas

Chapter 11. Company Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Segmental and Regional Analysis
11.1.4 Research & Development Expense
11.1.5 Recent strategies and developments:
11.1.5.1 Partnerships, Collaborations, and Agreements:
11.1.5.2 Product Launches and Product Expansions:
11.1.6 SWOT Analysis
11.2 AbbVie, Inc.
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
11.2.5.1 Partnerships, Collaborations, and Agreements:
11.2.5.2 Acquisition and Mergers:
11.2.6 SWOT Analysis
11.3 Johnson & Johnson (Johnson & Johnson Services, Inc.)
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Segmental &Regional Analysis
11.3.4 Research & Development Expenses
11.3.5 Recent strategies and developments:
11.3.5.1 Partnerships, Collaborations, and Agreements:
11.3.6 SWOT Analysis
11.4 Merck KGaA
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Segmental and Regional Analysis
11.4.4 Research & Development Expense
11.4.5 Recent strategies and developments:
11.4.5.1 Partnerships, Collaborations, and Agreements:
11.4.6 SWOT Analysis
11.5 Bristol Myers Squibb Company
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Regional Analysis
11.5.4 Research & Development Expenses
11.5.5 Recent strategies and developments:
11.5.5.1 Acquisition and Mergers:
11.5.6 SWOT Analysis
11.6 AstraZeneca PLC
11.6.1 Company Overview
11.6.2 Financial Analysis
11.6.3 Regional Analysis
11.6.4 Research & Development Expenses
11.6.5 SWOT Analysis
11.7 Sanofi S.A.
11.7.1 Company Overview
11.7.2 Financial Analysis
11.7.3 Segmental and Regional Analysis
11.7.4 Research & Development Expense
11.7.5 SWOT Analysis
11.8 Novartis AG
11.8.1 Company Overview
11.8.2 Financial Analysis
11.8.3 Segmental and Regional Analysis
11.8.4 Research & Development Expense
11.8.5 SWOT Analysis
11.9 Biogen, Inc.
11.9.1 Company Overview
11.9.2 Financial Analysis
11.9.3 Regional Analysis
11.9.4 Research & Development Expense
11.9.5 SWOT Analysis
11.10. Amgen, Inc.
11.10.1 Company Overview
11.10.2 Financial Analysis
11.10.3 Regional Analysis
11.10.4 Research & Development Expenses
11.10.5 SWOT Analysis

TABLE 1 North America Antibody Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 North America Antibody Therapeutics Market, 2023 - 2030, USD Million
TABLE 3 North America Antibody Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 4 North America Antibody Therapeutics Market by Route of Administration, 2023 - 2030, USD Million
TABLE 5 North America Intravenous Market by Country, 2019 - 2022, USD Million
TABLE 6 North America Intravenous Market by Country, 2023 - 2030, USD Million
TABLE 7 North America Subcutaneous Market by Country, 2019 - 2022, USD Million
TABLE 8 North America Subcutaneous Market by Country, 2023 - 2030, USD Million
TABLE 9 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 11 North America Antibody Therapeutics Market by Format, 2019 - 2022, USD Million
TABLE 12 North America Antibody Therapeutics Market by Format, 2023 - 2030, USD Million
TABLE 13 North America Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Monoclonal Antibody Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Polyclonal Antibody Therapy Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Polyclonal Antibody Therapy Market by Country, 2023 - 2030, USD Million
TABLE 17 North America Bispecific Antibody Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Bispecific Antibody Market by Country, 2023 - 2030, USD Million
TABLE 19 North America Antibody fragment & Others Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Antibody fragment & Others Market by Country, 2023 - 2030, USD Million
TABLE 21 North America Antibody Therapeutics Market by Source, 2019 - 2022, USD Million
TABLE 22 North America Antibody Therapeutics Market by Source, 2023 - 2030, USD Million
TABLE 23 North America Human Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Human Market by Country, 2023 - 2030, USD Million
TABLE 25 North America Humanized Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Humanized Market by Country, 2023 - 2030, USD Million
TABLE 27 North America Chimeric Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Chimeric Market by Country, 2023 - 2030, USD Million
TABLE 29 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 31 North America Antibody Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 32 North America Antibody Therapeutics Market by End User, 2023 - 2030, USD Million
TABLE 33 North America Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 34 North America Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 35 North America Long-term care facilities Market by Country, 2019 - 2022, USD Million
TABLE 36 North America Long-term care facilities Market by Country, 2023 - 2030, USD Million
TABLE 37 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 38 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 39 North America Antibody Therapeutics Market by Disease Areas, 2019 - 2022, USD Million
TABLE 40 North America Antibody Therapeutics Market by Disease Areas, 2023 - 2030, USD Million
TABLE 41 North America Autoimmune & Inflammatory Diseases Market by Country, 2019 - 2022, USD Million
TABLE 42 North America Autoimmune & Inflammatory Diseases Market by Country, 2023 - 2030, USD Million
TABLE 43 North America Neurology Market by Country, 2019 - 2022, USD Million
TABLE 44 North America Neurology Market by Country, 2023 - 2030, USD Million
TABLE 45 North America Osteology Market by Country, 2019 - 2022, USD Million
TABLE 46 North America Osteology Market by Country, 2023 - 2030, USD Million
TABLE 47 North America Hematology Market by Country, 2019 - 2022, USD Million
TABLE 48 North America Hematology Market by Country, 2023 - 2030, USD Million
TABLE 49 North America Oncology Market by Country, 2019 - 2022, USD Million
TABLE 50 North America Oncology Market by Country, 2023 - 2030, USD Million
TABLE 51 North America Infectious Diseases Market by Country, 2019 - 2022, USD Million
TABLE 52 North America Infectious Diseases Market by Country, 2023 - 2030, USD Million
TABLE 53 North America Immunology Market by Country, 2019 - 2022, USD Million
TABLE 54 North America Immunology Market by Country, 2023 - 2030, USD Million
TABLE 55 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 56 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 57 North America Antibody Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 58 North America Antibody Therapeutics Market by Country, 2023 - 2030, USD Million
TABLE 59 US Antibody Therapeutics Market, 2019 - 2022, USD Million
TABLE 60 US Antibody Therapeutics Market, 2023 - 2030, USD Million
TABLE 61 US Antibody Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 62 US Antibody Therapeutics Market by Route of Administration, 2023 - 2030, USD Million
TABLE 63 US Antibody Therapeutics Market by Format, 2019 - 2022, USD Million
TABLE 64 US Antibody Therapeutics Market by Format, 2023 - 2030, USD Million
TABLE 65 US Antibody Therapeutics Market by Source, 2019 - 2022, USD Million
TABLE 66 US Antibody Therapeutics Market by Source, 2023 - 2030, USD Million
TABLE 67 US Antibody Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 68 US Antibody Therapeutics Market by End User, 2023 - 2030, USD Million
TABLE 69 US Antibody Therapeutics Market by Disease Areas, 2019 - 2022, USD Million
TABLE 70 US Antibody Therapeutics Market by Disease Areas, 2023 - 2030, USD Million
TABLE 71 Canada Antibody Therapeutics Market, 2019 - 2022, USD Million
TABLE 72 Canada Antibody Therapeutics Market, 2023 - 2030, USD Million
TABLE 73 Canada Antibody Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 74 Canada Antibody Therapeutics Market by Route of Administration, 2023 - 2030, USD Million
TABLE 75 Canada Antibody Therapeutics Market by Format, 2019 - 2022, USD Million
TABLE 76 Canada Antibody Therapeutics Market by Format, 2023 - 2030, USD Million
TABLE 77 Canada Antibody Therapeutics Market by Source, 2019 - 2022, USD Million
TABLE 78 Canada Antibody Therapeutics Market by Source, 2023 - 2030, USD Million
TABLE 79 Canada Antibody Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 80 Canada Antibody Therapeutics Market by End User, 2023 - 2030, USD Million
TABLE 81 Canada Antibody Therapeutics Market by Disease Areas, 2019 - 2022, USD Million
TABLE 82 Canada Antibody Therapeutics Market by Disease Areas, 2023 - 2030, USD Million
TABLE 83 Mexico Antibody Therapeutics Market, 2019 - 2022, USD Million
TABLE 84 Mexico Antibody Therapeutics Market, 2023 - 2030, USD Million
TABLE 85 Mexico Antibody Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 86 Mexico Antibody Therapeutics Market by Route of Administration, 2023 - 2030, USD Million
TABLE 87 Mexico Antibody Therapeutics Market by Format, 2019 - 2022, USD Million
TABLE 88 Mexico Antibody Therapeutics Market by Format, 2023 - 2030, USD Million
TABLE 89 Mexico Antibody Therapeutics Market by Source, 2019 - 2022, USD Million
TABLE 90 Mexico Antibody Therapeutics Market by Source, 2023 - 2030, USD Million
TABLE 91 Mexico Antibody Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 92 Mexico Antibody Therapeutics Market by End User, 2023 - 2030, USD Million
TABLE 93 Mexico Antibody Therapeutics Market by Disease Areas, 2019 - 2022, USD Million
TABLE 94 Mexico Antibody Therapeutics Market by Disease Areas, 2023 - 2030, USD Million
TABLE 95 Rest of North America Antibody Therapeutics Market, 2019 - 2022, USD Million
TABLE 96 Rest of North America Antibody Therapeutics Market, 2023 - 2030, USD Million
TABLE 97 Rest of North America Antibody Therapeutics Market by Route of Administration, 2019 - 2022, USD Million
TABLE 98 Rest of North America Antibody Therapeutics Market by Route of Administration, 2023 - 2030, USD Million
TABLE 99 Rest of North America Antibody Therapeutics Market by Format, 2019 - 2022, USD Million
TABLE 100 Rest of North America Antibody Therapeutics Market by Format, 2023 - 2030, USD Million
TABLE 101 Rest of North America Antibody Therapeutics Market by Source, 2019 - 2022, USD Million
TABLE 102 Rest of North America Antibody Therapeutics Market by Source, 2023 - 2030, USD Million
TABLE 103 Rest of North America Antibody Therapeutics Market by End User, 2019 - 2022, USD Million
TABLE 104 Rest of North America Antibody Therapeutics Market by End User, 2023 - 2030, USD Million
TABLE 105 Rest of North America Antibody Therapeutics Market by Disease Areas, 2019 - 2022, USD Million
TABLE 106 Rest of North America Antibody Therapeutics Market by Disease Areas, 2023 - 2030, USD Million
TABLE 107 Key Information - F. Hoffmann-La Roche Ltd.
TABLE 108 Key information - AbbVie, Inc.
TABLE 109 Key Information - Johnson & Johnson
TABLE 110 key Information - Merck KGaA
TABLE 111 Key Information - Bristol Myers Squibb Company
TABLE 112 KEY INFORMATION - AstraZeneca PLC
TABLE 113 Key Information - Sanofi S.A.
TABLE 114 Key Information - Novartis AG
TABLE 115 Key Information - Biogen, Inc.
TABLE 116 Key Information - Amgen, Inc.

List of Figures
FIG 1 Methodology for the research
FIG 2 North America Antibody Therapeutics Market, 2019 - 2030, USD Million
FIG 3 Porter's Five Forces Analysis - Antibody Therapeutics Market
FIG 4 Key Factors Impacting Antibody Therapeutics Market
FIG 5 North America Antibody Therapeutics Market share by Route of Administration, 2022
FIG 6 North America Antibody Therapeutics Market share by Route of Administration, 2030
FIG 7 North America Antibody Therapeutics Market by Route of Administration, 2019 - 2030, USD Million
FIG 8 North America Antibody Therapeutics Market share by Format, 2022
FIG 9 North America Antibody Therapeutics Market share by Format, 2030
FIG 10 North America Antibody Therapeutics Market by Format, 2019 - 2030, USD Million
FIG 11 North America Antibody Therapeutics Market share by Source, 2022
FIG 12 North America Antibody Therapeutics Market share by Source, 2030
FIG 13 North America Antibody Therapeutics Market by Source, 2019 - 2030, USD Million
FIG 14 North America Antibody Therapeutics Market share by End User, 2022
FIG 15 North America Antibody Therapeutics Market share by End User, 2030
FIG 16 North America Antibody Therapeutics Market by End User, 2019 - 2030, USD Million
FIG 17 North America Antibody Therapeutics Market share by Disease Areas, 2022
FIG 18 North America Antibody Therapeutics Market share by Disease Areas, 2030
FIG 19 North America Antibody Therapeutics Market by Disease Areas, 2019 - 2030, USD Million
FIG 20 North America Antibody Therapeutics Market share by Country, 2022
FIG 21 North America Antibody Therapeutics Market share by Country, 2030
FIG 22 North America Antibody Therapeutics Market by Country, 2019 - 2030, USD Million
FIG 23 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 24 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 25 Recent strategies and developments: AbbVie, Inc.
FIG 26 Swot Analysis: AbbVie, Inc.
FIG 27 Swot Analysis: Johnson & Johnson
FIG 28 Swot Analysis: Merck KGaA
FIG 29 SWOT Analysis: Bristol Myers Squibb Company
FIG 30 SWOT Analysis: AstraZeneca PLC
FIG 31 Swot Analysis: Sanofi S.A.
FIG 32 SWOT Analysis: Novartis AG
FIG 33 SWOT Analysis: Biogen, Inc.
FIG 34 Swot Analysis: Amgen, Inc.